The single-arm TRITON2 study demonstrated the efficacy of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer.1,2 Results from the study (ClinicalTrials.gov identifier NCT02952534) led to the approval of rucaparib in this setting.
Rucaparib is an inhibitor of the PARP1, PARP2, and PARP3 enzymes, which play a role in DNA repair.
Results of the single-arm TRITON2 study were published earlier this year and resulted in FDA approval of rucaparib in men with metastatic castration-resistant prostate cancer.
TRITON3, an open-label phase III trial of rucaparib is currently ongoing. The study is comparing rucaparib with physician’s choice of therapy in men with metastatic castration-resistant prostate cancer associated with homologous recombination gene deficiency.
1. Abida W, Campbell D, Patnaik A, et al: Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: Analysis from the phase 2 TRITON2 study. Clin Ca Res. February 21, 2020 (early release online).
2. Abida W, Campbell D, Patnaik A, et al: Preliminary results from the TRITON2 study of rucaparib in patients with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer: Updated analyses. Ann Oncol 30:v327-v328, 2019.